AI Article Synopsis
- A study investigated the link between weight changes and lung function decline in young adults, analyzing data from a large European health survey over a 20-year period.
- Researchers found that both moderate and high weight gain led to significant declines in lung function measures (FVC and FEV) in individuals, particularly those who were obese at the start.
- Conversely, individuals who lost weight showed less decline in lung function, highlighting the importance of weight management for preserving lung health throughout adulthood.
Article Abstract
Background: Previous studies have reported an association between weight increase and excess lung function decline in young adults followed for short periods. We aimed to estimate lung function trajectories during adulthood from 20-year weight change profiles using data from the population-based European Community Respiratory Health Survey (ECRHS).
Methods: We included 3673 participants recruited at age 20-44 years with repeated measurements of weight and lung function (forced vital capacity (FVC), forced expiratory volume in 1 s (FEV)) in three study waves (1991-93, 1999-2003, 2010-14) until they were 39-67 years of age. We classified subjects into weight change profiles according to baseline body mass index (BMI) categories and weight change over 20 years. We estimated trajectories of lung function over time as a function of weight change profiles using population-averaged generalised estimating equations.
Results: In individuals with normal BMI, overweight and obesity at baseline, moderate (0.25-1 kg/year) and high weight gain (>1 kg/year) during follow-up were associated with accelerated FVC and FEV declines. Compared with participants with baseline normal BMI and stable weight (±0.25 kg/year), obese individuals with high weight gain during follow-up had -1011 mL (95% CI -1.259 to -763) lower estimated FVC at 65 years despite similar estimated FVC levels at 25 years. Obese individuals at baseline who lost weight (<-0.25 kg/year) exhibited an attenuation of FVC and FEV declines. We found no association between weight change profiles and FEV/FVC decline.
Conclusion: Moderate and high weight gain over 20 years was associated with accelerated lung function decline, while weight loss was related to its attenuation. Control of weight gain is important for maintaining good lung function in adult life.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231449 | PMC |
| http://dx.doi.org/10.1136/thoraxjnl-2019-213880 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Behavior-change lifestyle interventions for the treatment of obesity in children and adolescents: A scoping review.
Ann N Y Acad Sci
December 2024
National Institute of Health Data Science, Peking University, Beijing, China.
Behavior-change lifestyle interventions are fundamental in children and adolescent obesity management. This scoping review discusses optimal behavior-change lifestyle interventions in the treatment of overweight and obesity in children and adolescents. A literature search on diet, physical activity, and behavioral intervention for obesity treatment in children and adolescents aged 0-19 years was conducted in the Cochrane Library, MEDLINE (OVID), EMBASE, and ClinicalTrials.
View Article and Find Full Text PDFInvolvement of gut microbiota in chlorpyrifos-induced subchronic toxicity in mice.
Arch Toxicol
December 2024
Laboratory of Molecular Toxicology, State Key Laboratory of Integrated Management of Pest Insects and Rodents, Institute of Zoology, Chinese Academy of Sciences, 1-5 Beichenxilu Road, Beijing, 100101, China.
Chlorpyrifos (CPF) is one of the most widely used organophosphorus pesticides all over the world. Unfortunately, long-term exposure to CPF may cause considerable toxicity to organisms. Some evidence suggests that the intestinal microbial community may be involved in regulating the toxicity of CPF.
View Article and Find Full Text PDFIdentifying the location-dependent adipose tissue bacterial DNA signatures in obese patients that predict body weight loss.
Gut Microbes
December 2025
Institut National de la Santé et de la Recherche Médicale (INSERM), InCOMM Intestine ClinicOralOmics Metabolism & Microbiota UMR1297 Inserm / Université Toulouse III, Toulouse, France.
Recent sets of evidence have described profiles of 16S rDNA sequences in host tissues, notably in fat pads that are significantly overrepresented and can serve as signatures of metabolic disease. However, these recent and original observations need to be further detailed and functionally defined. Here, using state-of-the-art targeted DNA sequencing and discriminant predictive approaches, we describe, from the longitudinal FLORINASH cohort of patients who underwent bariatric surgery, visceral, and subcutaneous fat pad-specific bacterial 16SrRNA signatures.
View Article and Find Full Text PDFMetabolic Syndrome: An Updated Review on Diagnosis and Treatment for Primary Care Clinicians.
J Prim Care Community Health
December 2024
Lehigh Valley Health Network Family Medicine Residency, Allentown, PA, USA.
Objective: Metabolic syndrome is a cluster of cardiovascular risk factors (central obesity, hypertension, dyslipidemia, and insulin resistance) that affects between 12.5% and 31.4% of adults worldwide.
View Article and Find Full Text PDFSafety of SGLT-2 inhibitors in the management of heart failure in the adult congenital heart disease patient population.
Int J Cardiol Congenit Heart Dis
March 2024
Division of Cardiology, Department of Medicine, Loma Linda University, Loma Linda, CA, USA.
Background: Sodium glucose transporter 2 inhibitors (SGLT-2i) have shown safety and efficacy in patients with heart failure (HF). However, evidence for the use of SGLT-2i in adult congenital heart disease (ACHD) patients with HF is limited.
Methods: We performed a retrospective, single center analysis of 18 patients (>18 years of age) with ACHD and a diagnosis of HF who were initiated on an SGLT-2i.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!